Drug Delivery

(PETS) Small Caps, Big Yields

Finding small cap companies that pay a dividend is no easy feat. At this stage in a company’s growth trajectory, cash flow is usually too erratic or is immediately put into growing the company.

However, there are those rare small cap jewels that offer yields above 3%. Aside from master limited...

18Mar2014 | | Comments Off on (PETS) Small Caps, Big Yields | Continued

(ELN) Elan Provides Strategic Update

Elan Corporation (ELN) recently provided an update on its strategic plans for the future. The company plans several acquisitions and has other strategic initiatives lined up for further advancement.

Elan is set to acquire privately...

15Aug2013 | | Comments Off on (ELN) Elan Provides Strategic Update | Continued

(ALKS) Pipeline Progress at Alkermes

Alkermes (ALKS) recently announced encouraging top-line data from a phase II study (n=142) on ALKS 5461. The study evaluated the safety and efficacy of ALKS 5461 across two doses for the treatment of major depressive disorder (MDD)...

2May2013 | | Comments Off on (ALKS) Pipeline Progress at Alkermes | Continued

(ELN) Elan Responds to Royalty Pharma Offer

Elan Corporation’s (ELN) Board of Directors recently responded to Echo Pharma Acquisition Limited’s (“Royalty Pharma”) offer to acquire Elan’s shares under Rule 2.5 of the Irish Takeover Rules.

Elan stated that...

27Apr2013 | | Comments Off on (ELN) Elan Responds to Royalty Pharma Offer | Continued

(ELN) Elan Corporation to Sell Remaining Alkermes Stake

Elan Corporation plc (ELN) recently decided to sell its remaining 7.8 million ordinary shares in Alkermes plc (ALKS) pursuant to Rule 144 under the US Securities Act...

11Feb2013 | | Comments Off on (ELN) Elan Corporation to Sell Remaining Alkermes Stake | Continued

(ALKS) Alkermes Maintains Fiscal 2013 View

Alkermes plc (ALKS) recently reaffirmed its view for fiscal 2013 (ending March 31, 2013). The company continues to expect adjusted earnings per share in the range of $0.88-$1.02. The Zacks Consensus Estimate is pegged below the company’s...

15Jan2013 | | Comments Off on (ALKS) Alkermes Maintains Fiscal 2013 View | Continued

(PETS) PetMed Express Stays at Neutral

We have reaffirmed our Neutral recommendation on PetMed Express (PETS), following its second-quarter fiscal 2013 results.

PetMed reported earnings per share (EPS) of 20 cents in the quarter, a penny ahead of the year-ago quarter...

2Jan2013 | | Comments Off on (PETS) PetMed Express Stays at Neutral | Continued

(ALKS) Alkermes Plc – Bull of the Day

We are upgrading Alkermes Plc (ALKS) to Outperform following the upwardly revised adjusted earnings guidance provided by the company for fiscal 2013. The guidance was boosted following the successful completion of the refinancing...

19Oct2012 | | Comments Off on (ALKS) Alkermes Plc – Bull of the Day | Continued

(ALKS) Alkermes’ Debt Refinanced

Recently, Alkermes plc (ALKS) announced the successful completion of the refinancing of its previously outstanding senior secured bank debt. Through this move, the company brought down its total debt outstanding by $75 million to...

9Oct2012 | | Comments Off on (ALKS) Alkermes’ Debt Refinanced | Continued

(ALKS) Back to Neutral on Alkermes

We are moving back to a Neutral recommendation on Alkermes plc (ALKS) as we believe the stock is fairly valued at current levels. Our target price is $20.00. The stock carries a Zacks #3 Rank (Hold rating) in the short run.

The...

9Oct2012 | | Comments Off on (ALKS) Back to Neutral on Alkermes | Continued

(ALKS) Alkermes, Plc – Bull of the Day

We are upgrading Alkermes, Plc (ALKS) to Outperform following the impressive results delivered by the company in the final quarter of fiscal 2012 (the second full quarter following its merger with EDT). Alkermes beat the Zacks Consensus...

11Jul2012 | | Comments Off on (ALKS) Alkermes, Plc – Bull of the Day | Continued

(ALKS) Risk-Reward Balanced at Alkermes

We are maintaining a Neutral rating on Alkermes (ALKS) with a target price of $18.00.

Last month, Alkermes released its third quarter fiscal 2012 (ended December 31, 2011) financial results.  This was the first full quarter...

7Mar2012 | | Comments Off on (ALKS) Risk-Reward Balanced at Alkermes | Continued

(HSP) Hospira Incorporated – Bear of the Day

Hospira Inc.’s (HSP) third quarter preliminary results were below expectations due to continued manufacturing problems at the company’s Rocky Mountain facility. The facility is expected to continue functioning below full...

27Oct2011 | | 0 comments | Continued

(ALKS) Alkermes Analyst Maintains Neutral Rating on Shares

We are maintaining our Neutral recommendation on Alkermes, Inc. (ALKS). Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous...

1Sep2011 | | 0 comments | Continued

(PETS) PetMed Still Underperforms

Recently, we reaffirmed our Underperform recommendation on PetMed Express (PETS) with a target price of $11.00.

PetMed has been reporting disappointing results over the past few quarters. Lower revenues coupled with higher...

5Jul2011 | | 0 comments | Continued

(ALKS) Alkermes Presents Encouraging Data

Recently, Alkermes Inc. (ALKS) presented encouraging top line data from an early stage study of its schizophrenia candidate ALKS 9070 (n=32).  ALKS 9070 is a once-monthly injectable extended release version of Bristol-Myer...

1Jul2011 | | 0 comments | Continued

(PETS) PetMed Express – Bear of the Day

PetMed Express (PETS) reported a disappointing quarter with EPS of $0.19, missing the Zacks Consensus Estimate of $0.22 and the year-ago quarter’s $0.27. While new order sales declined on fewer new customers, revenues increased...

1Jul2011 | | 0 comments | Continued

(ALKS) Alkermes Evenly Poised

We are maintaining our Neutral recommendation on Alkermes, Inc. (ALKS) with a target price of $18.00.

Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop...

24Jun2011 | | 0 comments | Continued

(PETS) PetMed Express – Bear of the Day

PetMed Express (PETS) reported a disappointing quarter with EPS of $0.19 missing the Zacks Consensus Estimate of $0.22 and the year-ago quarter’s $0.27. Both gross and operating margins declined due to higher product and advertising...

16May2011 | | 0 comments | Continued

(ALKS) Stock Market News for May 10, 2011 – Market News

After suffering a slump last week, commodities made a strong comeback yesterday and lifted the benchmarks higher. Energy shares joined in on the uptrend as crude prices once again rose above $100 per barrel. Meanwhile fresh worries about Greece’s credit ratings partially limited gains.

The...

10May2011 | | 0 comments | Continued

(ALKS) Alkermesto Buy Elan Unit for $960 Million

Recently, Alkermes, Inc. (ALKS) inked a deal with Elan Corporation (ELN) to buy the latter’s Elan Drug Technologies (EDT) segment. The EDT segment is the drug delivery...

9May2011 | | 0 comments | Continued

(HSP) Hospira Earnings Beat The Street – Backs Outlook

Hospira Inc. (HSP) reported earnings per share of 93 cents for the first quarter of 2011, well above the Zacks Consensus Estimate of 79 cents. Earnings benefited from strong US sales of the generic version of Sanofi Aventis’...

3May2011 | | 0 comments | Continued

(ALKS) Company News for April 18, 2011 – Corporate Summary

• Chesapeake Energy Corp’s. (NYSE:CHK) share prices gained 0.25% after it announced plans to buy Bronco Drilling Co. (NASDAQ:BRNC) for $11 a share. The purchase price represents a 24% premium...

18Apr2011 | | 0 comments | Continued

(ALKS) Alkermes 2010 Second Quarter Revenues Rise – View Lowered

Alkermes Inc.’s (ALKS) second quarter fiscal 2011 net loss (excluding special items) of 6 cents per share compared unfavorably with the year-ago loss of 5 cents per share. The Zacks Consensus Estimate was a loss of 15 cents per...

24Nov2010 | | 0 comments | Continued

(ELN) Elan Quarterly Report Matches Earnings Estimates

Elan Corporation plc (ELN) reported loss per share of 7 cents for the third quarter of 2010, in line with the Zacks Consensus Estimate but way below the year-ago earnings of 11 cents per share. The year-ago quarter saw Elan recording...

3Nov2010 | | 0 comments | Continued

(ALKS) Alkermes’ Vivitrol Earns US Food and Drug Administration Clearance

Alkermes Inc. (ALKS) received a boost when the US Food and Drug Administration (FDA) cleared its drug Vivitrol (naltrexone for extended-release injectable suspension) for the prevention of relapse to opioid dependence after opioid...

17Oct2010 | | 0 comments | Continued

(PETS) PetMed Express Incorporated – Bear of the Day

PetMed Express, Inc. (PETS) reported first-quarter fiscal 2011 EPS of $0.32, way below the Zacks Consensus Estimate of $0.38 and the year-ago quarter’s $0.36. The company witnessed a decline in revenues due to a lack of television...

18Aug2010 | | 0 comments | Continued

(PETS) PetMed Express Incorporated – Bear of the Day

PetMed Express, Inc. (PETS) reported first-quarter fiscal 2011 EPS of $0.32, way below the Zacks Consensus Estimate of $0.38 and the year-ago quarter’s $0.36. The company witnessed a decline in revenues due to a lack of television...

18Aug2010 | | 0 comments | Continued

(ALKS) Alkermes Earnings Report Shows Revenues Dipped

Alkermes Inc.’s (ALKS) first-quarter fiscal 2011 net loss of  14 cents per share compared unfavorably with the year-ago loss of 2 cents per share. The Zacks Consensus Estimate was a loss of 14 cents per share.

Quarterly...

10Aug2010 | | 0 comments | Continued

(HSP) Hospira Second Quarter 2010 Earnings Preview

Hospira Inc. (HSP) is scheduled to report its second quarter 2010 results on Wednesday, July 28, before the opening bell. The Zacks Consensus Estimate for the quarter is earnings of 79 cents per share (with an upside of 2.53%), compared...

2Aug2010 | | 0 comments | Continued